share_log

Today's biggest pre-market stock movers: PHUN, CRTD, DWAC and more

Benzinga Real-time News ·  Oct 22, 2021 08:10  · Movers

Gainers

  • $Phunware Inc(PHUN.US)$ rose 300% to $6.10 in pre-market trading. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World Acquisition as traders circulated an article from May 2020 highlight a partnership between Phunware and the former Trump campaign.

  • $Creatd Inc(CRTD.US)$ rose 105.4% to $6.00 in pre-market trading after gaining around 8% on Thursday. Creatd recently highlighted debut of new look, updated packaging for camp, the direct-to-consumer healthy food brand incubated under the company’s e-commerce unit.

  • $DIGITAL WORLD ACQUISITION CORP(DWAC.US)$ rose 49% to $67.76 in pre-market trading. Digital World Acquisition surged around 357% on Thursday following an announcement the company will merge with Trump Media & Technology Group.

  • $DatChat(DATS.US)$ shares rose 18.8% to $10.50 in pre-market trading after declining 3% on Thursday.

  • $GROM SOCIAL ENTERPRISES INC(GROM.US)$ rose 10.7% to $3.93 in pre-market trading. Grom Social Enterprises amended private placement to increase total raise to up to $10.4 million.

  • $T2 Biosystems(TTOO.US)$ rose 10.2% to $0.91 in pre-market trading after the company announced distribution agreements in key Asia-Pacific markets.

  • $Salem Media Group(SALM.US)$ rose 8.9% to $4.04 in pre-market trading after jumping 12% on Thursday.

  • $Takung Art(TKAT.US)$ rose 8.1% to $7.50 in pre-market trading.

  • $Cidara Therapeutics Inc(CDTX.US)$ rose 5.7% to $1.68 in pre-market trading. Cidara Therapeutics recently priced its 14.8 million share offering at $1.55 per share.

Losers

  • $Metacrine Inc(MTCR.US)$ fell 49.6% to $1.93 in pre-market trading after the company reported interim results for the MET642 Phase 2a trial in patients with NASH and announced a strategic reprioritization of its clinical development programs

  • $Snap Inc(SNAP.US)$ shares fell 19.9% to $60.16 in pre-market trading. Snap reported upbeat earnings for its third quarter, while sales missed expectations. The company also issued Q4 sales guidance below estimates.

  • $Socket Mobile(SCKT.US)$ shares fell 17.8% to $7.38 in pre-market trading after the company announced Q3 earnings results.

  • $Lightbridge Corp(LTBR.US)$ shares fell 15.7% to $6.82 in pre-market trading after gaining over 8% on Thursday. Lightbridge completed work under U.S. Department of Energy GAIN Voucher at Idaho National Lab to support irradiation testing of Lightbridge fuel.

  • $Camber Energy, Inc.(CEI.US)$ shares fell 13% to $1.41 in pre-market trading after declining over 10% on Thursday.

  • $Sesen Bio(SESN.US)$ fell 12% to $1.10 in pre-market trading. The FDA recently granted Sesen Bio’s request for a Type A meeting to discuss issued raised in the FDA's Complete Response Letter related to vicineum.

  • $Seaport Global Acquisition Corp(SGAM.US)$ fell 11.4% to $11.34 in pre-market trading after surging 33% on Thursday.

  • $Vinco Ventures(BBIG.US)$ fell 10.9% to $5.34 in pre-market trading. The company recently reported the CEO and CFO resigned and transitioned into other roles within the company at Vinco Venture's parent company ZASH Global Media and a Vinco Ventures subsidiary, Cryptyde.

  • $Huadi International Group(HUDI.US)$ fell 10.9% to $12.65 in pre-market trading after jumping 20% on Thursday.

  • $Kaival Brands Innovations(KAVL.US)$ fell 10.3% to $1.57 in pre-market trading after dipping over 10% on Thursday.

  • $Xiaobai Maimai(HX.US)$ shares fell 10.2% to $8.21 in pre-market trading after dropping over 50% on Thursday.

  • $Intel(INTC.US)$ shares fell 9.9% to $50.45 in pre-market trading. Intel reported upbeat earnings for the third quarter, while sales missed estimates.

  • $INMED PHARMACEUTICALS INC(INM.US)$ shares fell 9.4% to $1.73 in pre-market trading. InMed Pharmaceuticals recently announced completion of BayMedica acquisition.

  • $Fangdd Network(DUO.US)$ fell 8.9% to $1.23 in pre-market trading after jumping over 28% on Thursday.

  • $Benitec Biopharma Ltd(BNTC.US)$ fell 8.8% to $3.39 in pre-market trading.

  • $LumiraDx(LMDX.US)$ fell 8.4% to $8.25 in pre-market trading. LumiraDx recently received approval for its COVID-19 antigen test for use in India.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment